2 completed, 2 terminated. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Quantum Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication FSD-F2R6-A-CP, Placebo - Acute Alcohol Intoxication | Not applicable | Completed | Quantum Biopharma | 26 | 2024-07-12 | 2025-05-22 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers Lucid-21-302, Placebo - Healthy Participants | Phase 1 | Completed | Quantum Biopharma | 40 | 2023-03-22 | 2023-08-29 |
| Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) FSD201, Placebo - Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic | Phase 2 | Terminated | Quantum Biopharma | 2 | 2023-01-19 | 2026-04-21 |
| Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19 FSD201, Placebo, Standard of Care for Covid-19 - COVID-19 | Phase 2 | Terminated | Quantum Biopharma | 53 | 2020-12-14 | 2022-12-05 |
Alcoholic Intoxication (1) · COVID-19 (1) · Mast Cell Activation Syndrome (1)
Standard of Care (1)
United States (3) · Canada (2)
Andrzej Chruscinski, MD (1) · Eric Sikorski, PhD (1) · Isabella Szeto, MD (1)